- Home
- OMCL
as 11-15-2024 4:00pm EST
Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | FORT WORTH |
| Market Cap: | 2.0B | IPO Year: | 2001 |
| Target Price: | $50.83 | AVG Volume (30 days): | 598.3K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.12 - $55.75 | Next Earning Date: | 10-30-2024 |
| Revenue: | $1,064,205,999 | Revenue Growth: | -10.26% |
| Revenue Growth (this year): | -1.84% | Revenue Growth (next year): | 4.97% |
Latest Omnicell Inc. ($0.001 par value) News
OMCL Breaking Stock News: Dive into OMCL Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
OMCL: Lowering target price to $51.00
Zacks
11 days ago
Surging Earnings Estimates Signal Upside for Omnicell (OMCL) Stock
Argus Research
11 days ago
OMCL: Raising target price to $52.00
Simply Wall St.
15 days ago
Omnicell Third Quarter 2024 Earnings: EPS Beats Expectations
Simply Wall St.
16 days ago
A Look At The Fair Value Of Omnicell, Inc. (NASDAQ:OMCL)
Zacks
17 days ago
OMCL Stock Soars on Q3 Earnings & Revenue Beat, '24 EPS View Raised
Zacks
17 days ago
Omnicell, Inc. (OMCL) Soars to 52-Week High, Time to Cash Out?
MT Newswires
17 days ago
BofA Securities Downgrades Omnicell to Neutral From Buy, Adjusts Price Target to $57 From $44
Compare OMCL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OMCL Omnicell Inc. ($0.001 par value) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.